Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...

What is Genetic Engineering?

What is Genetic Engineering?

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A precision gene-engineered B cell medicine producing sustained levels of active factor IX for hemophilia B therapy.

Molecular therapy : the journal of the American Society of Gene Therapy·2025

Same author

Dopaminergic Therapies May Decrease Risk of Early and Intermediate Non-exudative Age-related Macular Degeneration Progression.

Ophthalmic surgery, lasers & imaging retina·2025

Same author

In vivo tracking of ex-vivo-generated <sup>89</sup>Zr-oxine-labeled plasma cells by PET in a non-human primate model.

Molecular therapy : the journal of the American Society of Gene Therapy·2025

Same author

Human plasma cells engineered to secrete bispecifics drive effective in vivo leukemia killing.

Molecular therapy : the journal of the American Society of Gene Therapy·2024

Same author

<i>In vivo</i> tracking of <i>ex vivo</i> generated <sup>89</sup> Zr-oxine labeled plasma cells by PET in a non-human primate model.

bioRxiv : the preprint server for biology·2024

Same author

Lentiviral gene therapy for X-linked chronic granulomatous disease recapitulates endogenous CYBB regulation and expression.

Blood·2022

Search research articles

Related Experiment Video

Updated: Jun 1, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Treating cancer with genetically engineered T cells.

Tristen S Park¹, Steven A Rosenberg, Richard A Morgan

¹National Institutes of Health, National Cancer Institute, Surgery Branch, Bethesda, MD 20892, USA.

Trends in Biotechnology

|June 14, 2011

Summary

Tumor-infiltrating lymphocytes (TILs) show promise in treating melanoma. Genetic engineering advances enable T-cell receptor (TCR) and chimeric antigen receptor (CAR) therapies for broader cancer treatment, demonstrating clinical efficacy.

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Related Experiment Videos

Last Updated: Jun 1, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Area of Science:

Immunotherapy
Oncology
Genetic Engineering

Background:

Ex vivo cultured tumor-infiltrating lymphocytes (TILs) can induce durable melanoma regression.
Generating TILs is not feasible for all patients and has limited success in other cancers.
Genetic engineering offers a solution by modifying T lymphocytes.

Purpose of the Study:

To review the development of T-cell receptor (TCR) and chimeric antigen receptor (CAR) gene transfer technology.
To discuss the expansion of these engineered T-cell therapies into various cancer types.
To highlight the recent clinical efficacy demonstrated by these advanced treatments.

Main Methods:

Discusses the advancements in genetic engineering for T-cell therapies.
Reviews the application of TCR and CAR gene transfer.
Summarizes clinical data on the efficacy of these engineered T-cell treatments.

Main Results:

Engineered T lymphocytes expressing TCRs or CARs can target tumor antigens.
These therapies have shown expanded applicability beyond melanoma.
Recent clinical studies demonstrate the efficacy of TCR and CAR gene transfer.

Conclusions:

TCR and CAR gene transfer technologies represent significant progress in cancer immunotherapy.
These engineered T-cell therapies offer a viable treatment option for a wider range of cancer patients.
The demonstrated clinical efficacy supports the continued development and application of these innovative treatments.